239 related articles for article (PubMed ID: 7084884)
21. Enhanced renal clearance of uric acid in hepatic cirrhosis.
Higuchi T; Nakamura T; Uchino H
Isr J Med Sci; 1981 Nov; 17(11):1015-8. PubMed ID: 7319788
[TBL] [Abstract][Full Text] [Related]
22. Altered kinetics of etozolin and its active metabolite ozolinone in hepatitis and hepatic cirrhosis with ascites.
Knauf H; Missmahl M; Schölmerich J; Gerok W; Mutschler E
Arzneimittelforschung; 1987 Dec; 37(12):1385-8. PubMed ID: 3449068
[TBL] [Abstract][Full Text] [Related]
23. Hepatic parenchymal cell volume and the indocyanine green tolerance test.
Hashimoto M; Watanabe G
J Surg Res; 2000 Aug; 92(2):222-7. PubMed ID: 10896825
[TBL] [Abstract][Full Text] [Related]
24. The effect of liver disease in man on the disposition of phenobarbital.
Alvin J; McHorse T; Hoyumpa A; Bush MT; Schenker S
J Pharmacol Exp Ther; 1975 Jan; 192(1):224-35. PubMed ID: 235636
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of benzoate-metabolizing capacity in patients with chronic liver disease: pharmacokinetic analysis.
Yamada S; Yamamoto T; Suou T; Fujii T; Takayama M; Amisaki T; Tabuchi F; Kobayashi J; Hasegawa M; Hoshino U
Res Commun Chem Pathol Pharmacol; 1992 Apr; 76(1):53-62. PubMed ID: 1518961
[TBL] [Abstract][Full Text] [Related]
26. [Hepatic elimination of indocyanine green and antipyrine in patients with chronic liver disease].
Kuntz HD; Meessen D; May B
Med Welt; 1982 Jun; 33(25):909-10. PubMed ID: 7109938
[No Abstract] [Full Text] [Related]
27. Comparison of indocyanine green clearance with Child's-Pugh score and hepatic histology: a multivariate analysis.
Mukherjee S; Rogers MA; Buniak B
Hepatogastroenterology; 2006; 53(67):120-3. PubMed ID: 16506389
[TBL] [Abstract][Full Text] [Related]
28. Serum leptin levels in patients with nonalcoholic chronic liver disease.
Nakamuta M; Tada S; Uchimura K; Enjoji M; Kinukawa N; Iwamoto H; Sugimoto R; Shimada M; Ohashi M; Sugimachi K; Nawata H
Hepatogastroenterology; 2001; 48(38):527-32. PubMed ID: 11379347
[TBL] [Abstract][Full Text] [Related]
29. [Studies on liver diseases using the indocyanine green test].
Huoranszki F; Jakab M; Wittman I; Aszódi Z; Rendes E
Dtsch Z Verdau Stoffwechselkr; 1972; 32(4):295-302. PubMed ID: 4662802
[No Abstract] [Full Text] [Related]
30. Effects of naftidrofuryl on the indocyanine green clearance and cardiovascular function of rats with liver cirrhosis.
Steinmann U; Braun R; Sippel H; Estler CJ
Arzneimittelforschung; 1990 Jun; 40(6):709-11. PubMed ID: 2397008
[TBL] [Abstract][Full Text] [Related]
31. [Comparative evaluation of the dyes bromsulphthalein and indocyanine green in liver function diagnosis].
Andree H; Berndt H
Z Arztl Fortbild (Jena); 1984; 78(22):931-6. PubMed ID: 6528633
[No Abstract] [Full Text] [Related]
32. Effect of liver blood flow and function on hepatic indocyanine green clearance measured directly in a cirrhotic animal model.
Jiao LR; El-Desoky AA; Seifalian AM; Habib N; Davidson BR
Br J Surg; 2000 May; 87(5):568-74. PubMed ID: 10792311
[TBL] [Abstract][Full Text] [Related]
33. Disposition of nafcillin in patients with cirrhosis and extrahepatic biliary obstruction.
Marshall JP; Salt WB; Elam RO; Wilkinson GR; Schenker S
Gastroenterology; 1977 Dec; 73(6):1388-92. PubMed ID: 913979
[TBL] [Abstract][Full Text] [Related]
34. Comparison of sulfobromophthalein and indocyanine green clearances in the cat.
Center SA; Bunch SE; Baldwin BH; Hornbuckle WE; Tennant BC
Am J Vet Res; 1983 Apr; 44(4):727-30. PubMed ID: 6869973
[TBL] [Abstract][Full Text] [Related]
35. Indocyanine green clearance test and model for end-stage liver disease score of patients with liver cirrhosis.
Sheng QS; Lang R; He Q; Yang YJ; Zhao DF; Chen DZ
Hepatobiliary Pancreat Dis Int; 2009 Feb; 8(1):46-9. PubMed ID: 19208514
[TBL] [Abstract][Full Text] [Related]
36. Carnitine metabolism in patients with chronic liver disease.
Krähenbühl S; Reichen J
Hepatology; 1997 Jan; 25(1):148-53. PubMed ID: 8985281
[TBL] [Abstract][Full Text] [Related]
37. The stimulant effect of drugs on indocyanine green clearance by the liver.
Melikian V; Eddy JD; Paton A
Gut; 1972 Oct; 13(10):755-8. PubMed ID: 5087064
[TBL] [Abstract][Full Text] [Related]
38. [Diagnostic value of the study of caffeine elimination in chronic liver diseases].
Darnót G; Nemesánszky E; Bariska J
Orv Hetil; 1995 Apr; 136(18):927-32. PubMed ID: 7739851
[TBL] [Abstract][Full Text] [Related]
39. Marked prolongation in disappearance half-time of plasma cholecystokinin-octapeptide in patients with hepatic cirrhosis.
Kanayama S; Himeno S; Kurokawa M; Shinomura Y; Kuroshima T; Okuno M; Tsuji K; Higashimoto Y; Ikei N; Hashimura E
Am J Gastroenterol; 1985 Jul; 80(7):557-60. PubMed ID: 4014106
[TBL] [Abstract][Full Text] [Related]
40. Drug disposition in liver disease.
Fruncillo RJ
Am Fam Physician; 1982 Dec; 26(6):167-9. PubMed ID: 7148640
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
